一种新的药物将早期乳腺癌患者的复发或死亡风险降低30%,这是几十年来取得的第一个重大进展。 A new drug reduced recurrence or death risk by 30% in early-stage breast cancer patients, marking the first major advance in decades.

一项名为lidERA的第三期试验发现,用于早期激素受体阳性,HER2阴性乳腺癌的试验药物giredestrant,与标准内分泌疗法相比,降低了30%的侵入性复发或死亡风险,36个月的侵入性无病生存率为92. 4%而不是89. 6%. A phase 3 trial called lidERA found that giredestrant, an investigational drug for early-stage hormone receptor-positive, HER2-negative breast cancer, reduced the risk of invasive recurrence or death by 30% compared to standard endocrine therapy, with 36-month invasive disease-free survival rates of 92.4% versus 89.6%. 关键患者分组的受益情况是一致的,该药物显示出一种有利的安全状况,停止治疗的患者较少。 The benefit was consistent across key patient subgroups, and the drug showed a favorable safety profile with fewer treatment discontinuations. 在2025年圣安东尼奥乳腺癌专题讨论会上介绍了结果,这是自2000年引入芳香酶抑制剂以来,这一常见乳腺癌子型的辅助疗法取得的第一个重大进展。 Results, presented at the 2025 San Antonio Breast Cancer Symposium, mark the first major advance in adjuvant therapy for this common breast cancer subtype since aromatase inhibitors were introduced in 2000.